Company intelligence / Profile preview

Akan Biosciences

Gaithersburg, Maryland, United Statesakanbio.com ↗

Ownership: Private
Employees: ~14
Development stage: Phase 2

Overview

StroMel™, their lead candidate for osteoarthritis of the knee, received FDA IND approval in February 2021 and is currently in Phase 2 clinical trials. The company also received a warning letter from the FDA in April 2024 regarding their Ayama™ product, which was being distributed without proper approvals.

Therapeutic areas: GastroenterologyPsychiatryRheumatologyDermatologyOther
Modalities: Stem cell-based therapeuticsAdipose-derived Stromal Vascular Fraction (SVF)
Industry: Biotech

Drug pipeline

2 assets

StroMel

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Akan Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akan Biosciences.

Explore the full profile